Acurx Pharmaceuticals (ACXP) director receives 2,150 stock options grant

Rhea-AI Filing Summary

Acurx Pharmaceuticals, Inc. director Joseph C. Scodari received a stock option grant related to his service on the company’s board. The award covers 2,150 stock options for common stock at an exercise price of $2.36 per share, with all options vesting on April 20, 2027.

The options expire on April 20, 2036. After this grant, Scodari holds 2,150 stock options directly, reflecting a compensation-related award rather than an open‑market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Scodari Joseph C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	2,150	$0.00	--

Holdings After Transaction: Stock Option — 2,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 2,150 options Exercise price: $2.36 per share Options after grant: 2,150 options +2 more

5 metrics

Stock options granted 2,150 options Grant for board service on April 20, 2026

Exercise price $2.36 per share Strike price for granted stock options

Options after grant 2,150 options Total stock options held directly following transaction

Vesting date April 20, 2027 Date when all granted options vest

Expiration date April 20, 2036 Final date to exercise the stock options

Key Terms

Stock Option, Director Compensation Policy, vest, exercise price

4 terms

Stock Option financial

"The award covers 2,150 stock options for common stock at $2.36."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Director Compensation Policy financial

"Award related to service under the Issuer's Director Compensation Policy."

vest financial

"The shares subject to the options shall vest on April 20, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"Stock options for common stock at an exercise price of $2.36 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scodari Joseph C

(Last) (First) (Middle)

C/O ACURX PHARMACEUTICALS, INC.,

259 LIBERTY AVENUE

(Street)

STATEN ISLAND NEW YORK 10305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acurx Pharmaceuticals, Inc. [ ACXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.36	04/20/2026		A		2,150(1)		04/20/2027	04/20/2036	Common Stock	2,150	$0	2,150	D

Explanation of Responses:

1. This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

	/s/ Kostantinos Skordalos, Power of Attorney For: Joseph C. Scodari	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acurx Pharmaceuticals (ACXP) director Joseph Scodari report on this Form 4?

Director Joseph C. Scodari reported receiving a stock option grant for 2,150 shares of Acurx Pharmaceuticals common stock. The grant is compensation for board service and is structured as options, not an open-market stock purchase or sale.

How many Acurx Pharmaceuticals (ACXP) options were granted to Joseph Scodari and at what price?

Joseph C. Scodari received 2,150 stock options tied to Acurx Pharmaceuticals common stock. The options have an exercise price of $2.36 per share, meaning that is the price at which he can purchase the underlying shares if he chooses to exercise.

When do Joseph Scodari’s Acurx Pharmaceuticals (ACXP) options vest and expire?

All of Joseph C. Scodari’s 2,150 stock options will vest on April 20, 2027. The options have an expiration date of April 20, 2036, giving him a long window after vesting to decide whether to exercise the award.

Is this Acurx Pharmaceuticals (ACXP) Form 4 a market purchase or sale of shares?

This Form 4 reflects a grant of stock options, not an open-market trade. The transaction code is “A” for grant or award acquisition, indicating compensation-related options rather than a direct buy or sell of Acurx Pharmaceuticals common stock.

How many Acurx Pharmaceuticals (ACXP) options does Joseph Scodari hold after this transaction?

Following this grant, Joseph C. Scodari holds 2,150 stock options directly. These options relate to Acurx Pharmaceuticals common stock and stem from his service on the board under the company’s Director Compensation Policy described in the footnote.